Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$61.4B
191M shares
52-week range
$244.82 – $377.54
61% from low
Sector
WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES
Exchange
NYSE
CS
P/S (TTM)
0.2
EV / FCF (TTM)
17.8
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
www.cencora.comNo one on the platform currently holds COR.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 121,940 | $41.2M |
| Bridgewater Associatesas of 2026-03-31 | 14,227 | $4.5M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-08-14 | $0.6000 | 2026-08-31 |
| 2026-05-15 | $0.6000 | 2026-06-01 |
| 2026-02-13 | $0.6000 | 2026-03-02 |
| 2025-11-14 | $0.6000 | 2025-12-01 |
| 2025-08-15 | $0.5500 | 2025-09-03 |
| 2025-05-16 | $0.5500 | 2025-06-02 |
| 2025-02-14 | $0.5500 | 2025-03-03 |
| 2024-11-15 | $0.5500 | 2024-11-29 |
| 2024-08-09 | $0.5100 | 2024-08-26 |
| 2024-05-09 | $0.5100 | 2024-05-24 |
No one on the platform has traded COR yet.
| 2024-02-08 | $0.5100 | 2024-02-26 |
| 2023-11-10 | $0.5100 | 2023-11-27 |
| Execution date | Ratio |
|---|---|
| 2009-06-16 | 2-for-1 |
| 2005-12-29 | 2-for-1 |
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 32.1% | 42.9% | — | — | — | |
| Rev. Growth % | 9.3% | 11.1% | ||||
| Profit Margin % | 0.5% | 0.6% | 0.4% | |||
| Free Cash Flow Margin % | 1.0% | 1.1% | 1.1% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +7.2% on the P/E track.
At today's price, your expected annual return is +12.4% on the P/E track.
At today's price, your expected annual return is +16.7% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $337.3B | +5.1% | $17.88 | $17.86–$17.91 | 18.3× | 8 |
| 2027 | $352.5B | +4.5% | $19.81 | $19.48–$20.12 | 16.5× | 6 |
| 2028 | $369.7B | +4.9% | $21.93 | $19.84–$24.47 | 14.9× | 3 |
| 2029 | $389.1B | +5.2% | $25.73 | $25.14–$26.10 | 12.7× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $4.35 | $4.48 | +3.0% |
| 2026-05-06 | $4.82 | $4.75 | -1.5% |
| 2026-02-04 | $4.05 | $4.08 | +0.7% |
| 2025-11-05 | $3.79 | $3.84 | +1.3% |
| 2025-08-06 | $3.85 | $4.00 | +3.9% |
| 2025-05-07 | $4.11 | $4.42 | +7.5% |
| 2025-02-05 | $3.50 | $3.73 | +6.6% |
| 2024-11-06 | $3.23 |
| $3.34 |
| +3.4% |
| $27M |
| — |
| CVETCovetrus, Inc. | $20.99 | +0.00% | $0 | — |
| GALNFGalenica AG | $99.85 | -13.17% | $5.0B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$NVS $COR $LLY $ABBV #commercialization #advertising When you think of memorable ads for any company, but especially for #healthcare or #eyecare, is there typically a #memorable starring:
View on StockTwits ↗
$OTLK $COR $REGN And the insider buying over the past few weeks deserves attention. 👀 2,772,165 shares bought for roughly $2.75M by GMS Ventures, CEO Robert Jahr and Director Faisal Ghiath Sukhtian. Plus 2,676,767 warrants at $1.10 attached to the GMS/CEO purchases. Insiders were willing to put millions into $OTLK at $0.99–$1.0482 while the stock is now trading around $0.61. Are they stupid… or do they know exactly what they’re buying? 👀
View on StockTwits ↗$OTLK $COR $REGN ~$152M market cap. ~$0.61/share. ~$62M cash. FDA approval secured. A commercial product. Expected 12-year U.S. reference product exclusivity. European commercialization underway. Cencora already in place as a strategic U.S. launch partner. U.S. launch targeted for year-end 2026. $50–75M expected revenue in the first 12 months and a >$500M annual U.S. sales base-case target before 2030. These are the kind of prospects biotech companies dream about BEFORE FDA approval. $OTLK already has the approval, product, cash, market, strategic partner and potentially 12 years of U.S. exclusivity. The valuation simply doesn’t seem to reflect what is already in place. LOL
View on StockTwits ↗#Congrats $OTLK on your 1st #FDA #approval! $ABC $COR check date for https://www.nasdaq.com/press-release/outlook-therapeuticsr-and-amerisourcebergen-announce-strategic-commercialization
View on StockTwits ↗$OTLK $COR $ABC Did you read or hear about #NextPharma and #Cencora in 2025?
View on StockTwits ↗$OTLK $COR OTLK — Next Catalysts | 1–8 Month Horizon 1️⃣ Confirmed U.S. launch / launch date 2️⃣ Exact LYTENAVA™ WAC 3️⃣ Major reimbursement / access milestone 4️⃣ Permanent HCPCS/J-Code application 5️⃣ First U.S. sales & sell-through data 6️⃣ Reorders & physician adoption 7️⃣ Permanent J-Code — April 2027 8️⃣ European expansion / new market launches 9️⃣ Anytime: Major institutional investors / U.S. commercial partnership 🔟 Anytime: New analyst coverage / Buy rating 1️⃣1️⃣ Potential regulatory tailwind for FDA-approved LYTENAVA™ vs. compounded bevacizumab
View on StockTwits ↗
$COR Price: $318.04 (+1.06%) Trend: Bearish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.06% RSI: 56.5 | Momentum: Moderate Volume: -58.0% vs avg Volatility: 2.11% Support: $300.65 | Resistance: $333.30 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai
View on StockTwits ↗
"Trumpflation" Is Real -- and Getting Worse. Here Are 2 Stocks That Turn Rising Prices Into Rising Profits: https://www.fool.com/investing/2026/08/19/trumpflation-is-real-and-getting-worse-here-are-2/ $COR $MCK
View on StockTwits ↗$OTLK $COR $OTLK Q3 10-Q + earnings call: the setup for Q4/Q1 FDA approval is done, and $OTLK targets U.S. launch before year-end 2026. The company raised ~$51.1M net to support commercialization. Launch readiness: • ~$5.04M inventory • ~$2.51M WIP, +162% vs. Sept. • Management says supply is sufficient for launch • U.S. manufacturing + distribution infrastructure • ~30 commercial + ~20 reimbursement specialists planned • European units +46% QoQ • Adjusted net loss down ~31% YoY Management's first-12-month U.S. net-revenue outlook is $50–75M, with >$500M annual U.S. sales as its base case before 2030. Launch ramps gradually: ~10% of first-year revenue in the first 3 months, accelerating toward ~50% by Q4. Q4 = launch execution. Q1 FY2027 = the real test: U.S. units, sell-through, reorders and revenue. The pieces are in place. Now we watch execution. Looks really good!
View on StockTwits ↗$OTLK do you think #supply will keep up with all the anticipated #demand? $COR $ABC #eyes #injections #wetAMD #bevacizumab $XBI
View on StockTwits ↗
$OTLK in case you mussed it. $COR (who has a commerialization and distribution agreement with $OTLK has quietlt been buying up the outlets that will be carrrying OTLKs drug. Could be nothing, could be important
View on StockTwits ↗$OTLK $ABC $COR https://eyewire.news/news/cencora-advances-specialty-leadership-through-acquisition-of-retina-consultants-of-america
View on StockTwits ↗$OTLK $ABC $COR https://eyewire.news/news/cencora-to-expand-retina-consultants-of-america-through-acquisition-of-eyesouth-partners-retina-business
View on StockTwits ↗
Cencora shares fell after the pharmaceutical distributor confirmed that some Walgreens volume previously handled outside its master provider agreement began shifting to rival distributors on July 1, 2026. While Cencora stressed that its core master supply agreement with Walgreens remains fully intact, investors were concerned about the loss of business from a major customer. Management reaffirmed its FY2026 adjusted diluted EPS guidance of $17.75–$17.95, noting the volume shift was anticipated and already reflected in its Aug. 5 commentary. Wells Fargo raised its price target to $395 from $331 while maintaining an Overweight rating, but the upgrade failed to offset selling pressure. CFO James Cleary’s previously disclosed plan to sell about 20,000 shares also added caution. Cencora dropped as much as 5.8% to a session low of $315.13, well below its 52-week high of $377.54. The broader market gained, with the S&P 500 up 0.3% and Nasdaq 0.6%. $COR
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.